The content on this site is intended for healthcare professionals only
At a press conference during the ASCO 2012 Annual Meeting in Chicago, June 1st - June 4th, Dr George Demetri presented results of an international phase III trial demonstrating that the new targeted oral drug, regorafenib, can improve outcomes for patients with gastrointestinal stromal tumours (GIST) that progress due to resistance to other available treatment options, including imatinib and sunitinib.
Domvanalimab, zimberelimab and FOLFOX shows durable survival in advanced HER2-negative GC/GEJC/EAC
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC
ESMO 2024: Latest in EGFR mutated NSCLC
The combination of regorafenib, nivolumab and SCRT shows promising efficacy as neoadjuvant therapy for locally advanced RC
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients
ASCO 2024: Lung cancer highlights
Nivolumab plus ipilimumab improves on chemo in previously untreated MSI-H/dMMR mCRC
